DECLARE TIMI 58 Trial Summary: Wiviott et al. randomized 17,160 patients with DMII (HbA1c 6.5-12%) who had multiple risk factors for or had established atherosclerotic CV disease to either dapagliflozin or a placebo. Their objective was to assess the cardiovascular safety profile of dapagliflozin, a selective inhibitor of SGLT2 in patients with type 2 diabetes. The results were promising and showed a significant decrease in CV death and HF hospitalizations (P=0.005). No difference was noted in the major adverse CV events. The authors of DECLARE TIMI 58 trial concluded that in patients with type 2 DM who had or were at risk for atherosclerotic CV disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE but did result in a lower rate of CV death or hospitalization for heart failure.